CSIMarket
 
Arcturus Therapeutics Holdings Inc   (ARCT)
Other Ticker:  
 

Arcturus Therapeutics Holdings Inc

Business Description


Arcturus Therapeutics Holdings Inc (Arcturus) is a clinical stage biopharmaceutical company engaged in the discovery, development, and commercialization of RNA medicines. The company is headquartered in San Diego, California, and was founded in 201

Arcturus has developed a proprietary mRNA drug delivery platform called STARR (Self-Transcribing Active Replicating RNA). This platform allows for rapid and flexible development of RNA medicines that can target a variety of diseases. The main focus of the company is on developing RNA medicines for the treatment of rare diseases and vaccines for infectious diseases.

The company has a pipeline of RNA medicines at various stages of development. ARCT-021 is the lead product candidate, which is being developed in collaboration with Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson). This candidate is being developed for the treatment of COVID-19 and is currently in Phase 2 clinical trials.

Arcturus is also developing ARCT-810, a potential treatment for ornithine transcarbamylase (OTC) deficiency, a rare genetic disorder. The company has received orphan drug designation for this candidate from the US FDA.

In addition to its own pipeline, Arcturus has formed partnerships with other pharmaceutical companies to develop RNA medicines for various indications. The company has partnerships with Ultragenyx Pharmaceutical and CureVac for the development of RNA medicines for rare diseases.

Arcturus has also entered into strategic alliances with various companies such as Thermo Fisher Scientific, Duke-NUS Medical School, and others to further advance its mRNA technology platform.

Arcturus has a strong management team with expertise in RNA technology, drug discovery, and development. The company has raised capital through various sources, including public offerings, private placements, and collaborations. As of 2021, the company has a market capitalization of approximately $4 billion.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com